Redox-sensitive polypeptides based on cell-penetrating peptides and their application in vaccine vectors
A vaccine carrier and membrane-penetrating peptide technology, applied in the field of biomedical materials and immunotherapy, can solve the problem of not causing cellular immunity and other problems
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0033] Embodiment 1: the design of polypeptide:
[0034] In the present invention, the advantages of the cell-penetrating peptide and the redox-responsive disulfide bond cross-linking agent are combined, and a polypeptide vaccine carrier is designed for antigen delivery. The specific structure of the polypeptide is: Cys-Trp-Trp-Arg8-Cys-Arg8-Cys-Arg8-Cys (including 2 tryptophans, 4 cysteines and 24 arginines: Cys-Trp-Trp- Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Cys-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Cys-Arg-Arg-Arg-Arg-Arg-Arg-Arg- Arg-Cys). The positively charged polypeptide carrier can combine with the negatively charged antigen protein through electrostatic attraction to form a nanocomplex, which is like a cage to wrap the antigen molecule. In nanocomposites, the sulfhydryl groups of cysteine are spontaneously oxidized to form disulfide bonds, and cross-linking occurs between polypeptides to form denser polypeptide / antigen condensates. The overall positively charged polypeptide / a...
Embodiment 2
[0035] Embodiment 2: the proportioning of polypeptide and ovalbumin OVA (purchased from Sigma-Aldrich)
[0036] Table 1 Particle size and potential of peptide / OVA with different mass ratios
[0037] The mass ratio of peptide and OVA Particle size (nm) PDI (polydispersity index) Potential (mV) 0.0625:1 65.055±1.209 0.218±0.006 -12.9±1.556 0.125:1 131.25±1.202 0.14±0.038 -11.75±0.354 0.25:1 8228.5±485.631 0.551±0.064 6±0.283 0.5:1 119.75±0.495 0.048±0.013 13.9±0.990 1:1 93.785±0.431 0.042±0.001 16.35±0.212 2:1 81.12±2.263 0.085±0.040 18.45±0.212
Embodiment 3
[0038] Embodiment 3: the preparation of vaccine preparation
[0039] Using ovalbumin OVA (purchased from Sigma-Aldrich) as the model antigen, vaccines of different formulations were prepared according to the following table, and the vaccine preparations used for subcutaneous injection are shown in Table 2 respectively.
[0040] Table 2 Different vaccine formulations used for subcutaneous injection
[0041]
[0042] Note: The peptide and antigen (ovalbumin OVA) need to be incubated at room temperature for 2 hours before use.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com